ArticleBMC psychiatry2026
Effectiveness of amisulpride augmentation versus other antipsychotics in clozapine-treated adolescents: a real-world retrospective study.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, we compared the clinical response to clozapine-amisulpride augmentation versus clozapine augmentation with other antipsychotics among children and adolescents with schizophrenia spectrum disorders in clinical practice. Crucially, the comparative efficacy of specific augmentation strategies in this vulnerable, early-onset population remains a largely unanswered question in current literature.
methodsSeventy-six inpatients who were treated with clozapine between 2013 and 2023 years at a tertiary care psychiatric university teaching hospital in Turkey were included in this retrospective study. Patients were divided into clozapine+amisulpride (n = 22) and clozapine+others (n = 54) groups according to their treatment regimen. Clinical response was assessed by comparing baseline and discharge Positive and Negative Syndrome Scale (PANSS) scores and response rates defined as ≥20% and ≥30% improvement. The effect of group assignment on clinical response was examined by multiple linear regression analysis while controlling for clozapine dose, baseline PANSS scores, and adjunctive antipsychotic load standardized via the Defined Daily Dose (DDD) method.
resultsMean age of the patients was 15.9 ± 2.3 years. Baseline PANSS total scores were similar between groups (p = 0.977). Mean changes in PANSS total scores (-25.1±34.7 vs. -25.5±32.1; p = 0.968) and subscale scores were not significantly different between groups at discharge. Response rates according to 30% and 20% thresholds were similar between groups (38.1% vs. 51.1%; p = 0.324, p = 0.954). In the multiple linear regression analysis, clozapine dose (p = 0.026) and baseline PANSS score (p < 0.001) were significant predictors of change in PANSS total score. In the negative subscale model, higher clozapine doses predicted greater symptom reduction (p = 0.028), whereas higher standardized doses of adjunctive antipsychotics predicted poorer improvement (p = 0.031).
conclusionsClozapine augmentation with amisulpride was not superior to augmentation with other antipsychotics in our sample. Treatment response appears to be driven more by clozapine dose and baseline severity. In addition, high standardized doses of adjunctive agents may counterproductively limit negative symptom recovery, perhaps due to secondary negative symptoms caused by excessive D2 receptor blockade. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.